Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Multi-center, Open-label, Single-dose Escalation and Expansion, Dose Escalation and Expansion Combination With Chemotherapy Study Evaluating the Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China

NCT04894825 is registered in ClinicalTrials.gov with FutureGen Biopharmaceutical (Beijing) Co., Ltd as lead sponsor.

NCT NCT04894825
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04894825 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Multi-center, Open-label, Single-dose Escalation and Expansion, Dose Escalation and Expansion Combination With Chemotherapy Study Evaluating the Safety, Tolerability and Pharmacokinetic Profile of M108 Monoclonal Antibody in Patients With Advanced Unresectable Solid Tumors in China
Lead sponsor
FutureGen Biopharmaceutical (Beijing) Co., Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
June 11, 2021
Completion date
December 30, 2024
Enrollment
152 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced unresectable solid tumors